Literature DB >> 12046731

Giant pituitary adenomas: clinical characteristics and surgical results.

J Garibi1, I Pomposo, G Villar, S Gaztambide.   

Abstract

Although most pituitary neoplasms are benign, some grow rapidly, spreading to extrasellar tissues. Definition of these 'giant' pituitary adenomas (PAs) is not clear. In order to clarify this question, we studied all pituitary macroadenomas operated in our hospital during the last 20 years, differentiating those with diameter > or = 3 cm (n = 43) and attempting to identify their typical features and prognosis. The reason for consultation was local in 58.3% of giant PAs, hormonal in 22.9% and tumour recurrence in 16.7%. Surgery was performed via a trans-sphenoidal approach in 92.5% of cases and succeeded in completely removing the tumour in only 27% of cases. In conclusion, we found that giant PAs are not a special type but the extreme case in the gradient of invasiveness of tumours of adenohypophyseal origin. They are characterized by a higher frequency of neuro-ophthalmological symptoms and hormonal deficits, and poorer response to surgical treatment.

Entities:  

Mesh:

Year:  2002        PMID: 12046731     DOI: 10.1080/02688690220131723

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  16 in total

1.  The current role of transcranial surgery in the management of pituitary adenomas.

Authors:  Ravindran Pratheesh; Simon Rajaratnam; Krishna Prabhu; Sunithi E Mani; Geeta Chacko; Ari G Chacko
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

2.  Volumetric classification of pituitary macroadenomas predicts outcome and morbidity following endoscopic endonasal transsphenoidal surgery.

Authors:  Christoph P Hofstetter; Michael J Nanaszko; Lynn L Mubita; John Tsiouris; Vijay K Anand; Theodore H Schwartz
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

Review 3.  Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of giant pituitary adenomas.

Authors:  Ricardo J Komotar; Robert M Starke; Daniel M S Raper; Vijay K Anand; Theodore H Schwartz
Journal:  Pituitary       Date:  2012-06       Impact factor: 4.107

4.  Pediatric giant pituitary adenomas: are they different from adults? A clinical analysis of a series of 12 patients.

Authors:  Sumit Sinha; Avijit Sarkari; A K Mahapatra; B S Sharma
Journal:  Childs Nerv Syst       Date:  2014-04-29       Impact factor: 1.475

5.  Intraoperative magnetic resonance imaging-guided transsphenoidal surgery for giant pituitary adenomas.

Authors:  Fabian Baumann; Christoph Schmid; René-Ludwig Bernays
Journal:  Neurosurg Rev       Date:  2009-10-13       Impact factor: 3.042

6.  Three-dimensional volumetric measurements in defining endoscope-guided giant adenoma surgery outcomes.

Authors:  Muhammad Omar Chohan; Ariana M Levin; Ranjodh Singh; Zhiping Zhou; Carlos L Green; Jacob J Kazam; Apostolos J Tsiouris; Vijay K Anand; Theodore H Schwartz
Journal:  Pituitary       Date:  2016-06       Impact factor: 4.107

7.  Comparison of lateral and superior walls of the pituitary fossa with clinical emphasis on pituitary adenoma extension: cadaveric-anatomic study.

Authors:  Erim Kursat; Selcuk Yilmazlar; Sibel Aker; Kaya Aksoy; Hakan Oygucu
Journal:  Neurosurg Rev       Date:  2007-10-12       Impact factor: 3.042

8.  Clinical features of sellar and suprasellar meningiomas.

Authors:  Ratchaneewan Kwancharoen; Ari M Blitz; Fabiana Tavares; Patrizio Caturegli; Gary L Gallia; Roberto Salvatori
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

9.  The influence of pituitary adenoma size on vision and visual outcomes after trans-sphenoidal adenectomy: a report of 78 cases.

Authors:  Ren-Wen Ho; Hsiu-Mei Huang; Jih-Tsun Ho
Journal:  J Korean Neurosurg Soc       Date:  2015-01-31

10.  Successful management of a giant pituitary lactosomatotroph adenoma only with cabergoline.

Authors:  Emre Bozkirli; Okan Bakiner; Emine Duygu Ersozlu Bozkirli; Eda Ertorer; Neslihan Bascil Tutuncu; Nilgun Guvener Demirag
Journal:  Case Rep Endocrinol       Date:  2013-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.